ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Understanding COVID-19 Treatment Options

photo

SPONSORED CONTENT -- (StatePoint) As COVID-19 restrictions are lifted, people are taking fewer precautions and the virus continues to spread in communities across the country. While getting vaccinated is the best way to prevent COVID-19, it’s also important to understand the potential treatment options available if you do get sick, particularly if you’re at high-risk for developing serious illness and complications.

As part of its mission to help prevent infection and severe illness from COVID-19, the American Lung Association has partnered with Regeneron Pharmaceuticals and GlaxoSmithKline to raise awareness about available treatment options. Here’s what to know:

Timing is Important

If you experience symptoms of COVID-19, it’s critical to get tested right away. If you’re a high-risk individual and test positive for COVID-19, speak to your healthcare provider about available treatment options that may help prevent severe illness and reduce the risk of hospitalization. Treatments, which include monoclonal antibodies (MABs), need to start as soon as possible and within 10 days of symptom onset to help prevent possible progression of severe illness.

Monoclonal Antibodies

MABs products that are authorized for emergency use by the Food and Drug Administration are used for patients who test positive for COVID-19, who are over 12 years old, are experiencing mild to moderate COVID-19 symptoms and who are at high risk of hospitalization. MABs are laboratory-made proteins that work by attaching to the replicating virus within an infected individual, which may enable the immune system to better recognize and stop the infection, preventing further illness from occurring. MAB treatment is given as an intravenous (IV) infusion or injection at a doctor’s office or outpatient center.

MAB Eligibility

It’s important to know whether you’re a higher-risk individual and eligible for MAB treatment. You’re considered high-risk if you’re aged 65 and older, have a chronic lung disease (including asthma, COPD, interstitial lung disease, cystic fibrosis or pulmonary hypertension) and if you have certain medical conditions. These conditions include being pregnant, overweight, or immunocompromised, as well as heart disease, diabetes, chronic kidney disease, sickle cell disease and neurodevelopmental disorders.

Treatments are widely available, and advocates say that efforts should be made to ensure that the communities most affected by COVID-19 have equitable access, this includes racial and ethnic minority groups, including Black, Latino/Hispanic and American Indian/Alaska Native communities.

If you do receive MABs, you should delay COVID-19 vaccination by at least 90 days.

For more information about COVID-19 and available treatments, visit lung.org.

Treatment options for COVID-19 are a step in the right direction to helping end this pandemic, say doctors, however it’s always preferable to prevent a disease than to treat it. Getting fully vaccinated against COVID-19 can help keep you from getting sick or spreading the infection to others.

*****

Photo Credit: (c) Digital Vision. / iStock via Getty Images Plus

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.